Cargando…

Nutraceuticals: opening the debate for a regulatory framework

Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Antonello, Cammarata, Silvia Miriam, Capone, Giacomo, Ianaro, Angela, Tenore, Gian Carlo, Pani, Luca, Novellino, Ettore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867125/
https://www.ncbi.nlm.nih.gov/pubmed/29433155
http://dx.doi.org/10.1111/bcp.13496
_version_ 1783308930309423104
author Santini, Antonello
Cammarata, Silvia Miriam
Capone, Giacomo
Ianaro, Angela
Tenore, Gian Carlo
Pani, Luca
Novellino, Ettore
author_facet Santini, Antonello
Cammarata, Silvia Miriam
Capone, Giacomo
Ianaro, Angela
Tenore, Gian Carlo
Pani, Luca
Novellino, Ettore
author_sort Santini, Antonello
collection PubMed
description Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of pharmaceutically active components contained in food that may improve health and reduce the risk of pathological conditions while enhancing overall well‐being. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and efficacy information or in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. An officially shared and accepted definition of nutraceuticals is still missing, as nutraceuticals are mostly referred to as pharma‐foods, a powerful toolbox to be used beyond the diet but before the drugs to prevent and treat pathological conditions, such as in subjects who may not yet be eligible for conventional pharmaceutical therapy. Hence, it is of utmost importance to have a proper and unequivocal definition of nutraceuticals and shared regulations. It also seems wise to assess the safety, mechanism of action and efficacy of nutraceuticals with clinical data. A growing demand exists for nutraceuticals, which seem to reside in the grey area between pharmaceuticals and food. Nonetheless, given specific legislation from different countries, nutraceuticals are experiencing challenges with safety and health claim substantiation.
format Online
Article
Text
id pubmed-5867125
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58671252018-03-29 Nutraceuticals: opening the debate for a regulatory framework Santini, Antonello Cammarata, Silvia Miriam Capone, Giacomo Ianaro, Angela Tenore, Gian Carlo Pani, Luca Novellino, Ettore Br J Clin Pharmacol Reviews Currently, nutraceuticals do not have a specific definition distinct from those of other food‐derived categories, such as food supplements, herbal products, pre‐ and probiotics, functional foods, and fortified foods. Many studies have led to an understanding of the potential mechanisms of action of pharmaceutically active components contained in food that may improve health and reduce the risk of pathological conditions while enhancing overall well‐being. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and efficacy information or in vitro and in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed. An officially shared and accepted definition of nutraceuticals is still missing, as nutraceuticals are mostly referred to as pharma‐foods, a powerful toolbox to be used beyond the diet but before the drugs to prevent and treat pathological conditions, such as in subjects who may not yet be eligible for conventional pharmaceutical therapy. Hence, it is of utmost importance to have a proper and unequivocal definition of nutraceuticals and shared regulations. It also seems wise to assess the safety, mechanism of action and efficacy of nutraceuticals with clinical data. A growing demand exists for nutraceuticals, which seem to reside in the grey area between pharmaceuticals and food. Nonetheless, given specific legislation from different countries, nutraceuticals are experiencing challenges with safety and health claim substantiation. John Wiley and Sons Inc. 2018-02-14 2018-04 /pmc/articles/PMC5867125/ /pubmed/29433155 http://dx.doi.org/10.1111/bcp.13496 Text en © 2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Santini, Antonello
Cammarata, Silvia Miriam
Capone, Giacomo
Ianaro, Angela
Tenore, Gian Carlo
Pani, Luca
Novellino, Ettore
Nutraceuticals: opening the debate for a regulatory framework
title Nutraceuticals: opening the debate for a regulatory framework
title_full Nutraceuticals: opening the debate for a regulatory framework
title_fullStr Nutraceuticals: opening the debate for a regulatory framework
title_full_unstemmed Nutraceuticals: opening the debate for a regulatory framework
title_short Nutraceuticals: opening the debate for a regulatory framework
title_sort nutraceuticals: opening the debate for a regulatory framework
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867125/
https://www.ncbi.nlm.nih.gov/pubmed/29433155
http://dx.doi.org/10.1111/bcp.13496
work_keys_str_mv AT santiniantonello nutraceuticalsopeningthedebateforaregulatoryframework
AT cammaratasilviamiriam nutraceuticalsopeningthedebateforaregulatoryframework
AT caponegiacomo nutraceuticalsopeningthedebateforaregulatoryframework
AT ianaroangela nutraceuticalsopeningthedebateforaregulatoryframework
AT tenoregiancarlo nutraceuticalsopeningthedebateforaregulatoryframework
AT paniluca nutraceuticalsopeningthedebateforaregulatoryframework
AT novellinoettore nutraceuticalsopeningthedebateforaregulatoryframework